Le Lézard
Classified in: Health, Business
Subject: ERN

Centric Health Announces Results for the Fourth Quarter and Full Year of 2017


Centric Health completes transitional year, establishing solid base for growth

TORONTO, March 20, 2018 /CNW/ - Centric Health Corporation ("Centric Health" or "the Company") (TSX: CHH), Canada's leading diversified healthcare services company, today reported its financial results for the fourth quarter ended December 31, 2017.

Highlights for the Fourth Quarter of 2017
(All comparative figures are for the fourth quarter of 2016)

With the completion of the Company's debt refinancing plan, during the second half of 2017, management has turned its primary focus to executing on the growth strategies and operational improvements for each of its business segments.

Highlights for the Full Year 2017
(All comparative figures are for the full year 2016)

Highlights subsequent to quarter-end

"In 2017 we completed what was a three-year transformation, which included selling off non-core businesses, making strategic acquisitions and strengthening the balance sheet," said Jack Shevel, Chairman and Interim CEO of Centric Health. "Moving into 2018, we are positioned as a leading provider of specialty pharmacy services and surgery and medical services with the resources to further consolidate and grow our position."

"In 2018 we will also look for opportunities to build on our position as a key provider to seniors to achieve solid growth," added Dr. Shevel. "This includes the launch of Karie, expected in the second half of the year, which will be a disruptor of traditional drug delivery for seniors at home, and also medical marijuana which has many applications in seniors care."

FINANCIAL RESULTS

Discontinued Operations

The Company's discontinued operations consist of the businesses divested as part of the sale of its Physiotherapy, Rehabilitation and Medical Assessments segment in 2015 and London Scoping Centre in 2016.

Selected Financial Information

(All amounts in the chart below are in thousands except per share, shares outstanding, and percentage data)


For the three month periods
ended December 31,

For the years ended
December 31,


2017

2016

2015

2017

2016

2015

(thousands of Canadian Dollars)

$

$

$

$

$

$

Revenue

42,328

41,827

41,549

168,967

167,363

160,753








Income (loss) from continuing
operations

(643)

585

(3,282)

996

(3,374)

(11,076)








Income (loss) from continuing
operations before interest expense
and income taxes

3,799

526

(98)

7,899

(8,800)

(6,626)








EBITDA1 from continuing operations

6,282

2,992

5,122

17,371

2,578

6,460

Adjusted EBITDA1 from continuing
operations

4,058

4,373

1,797

17,514

15,590

8,524


Per share - Basic and diluted

$0.02

$0.03

$0.01

$0.09

$0.09

$0.05

Adjusted EBITDA1 Margin from
continuing operations

9.6%

10.5%

4.3%

10.4%

9.3%

5.3%








Adjusted EBITDA1

4,058

4,363

6,613

17,514

15,466

31,788


Per share - Basic2 and diluted2

$0.02

$0.03

$0.04

$0.09

$0.09

$0.20

Adjusted EBITDA1 Margin

9.6%

10.3%

7.4%

10.4%

9.2%

9.1%








Net income (loss)

3,301

(1,746)

70,220

2,279

(19,806)

45,868


Per share - Basic2 and diluted2

$0.02

($0.01)

$0.44

$0.01

($0.12)

$0.29








Cash provided by operations

5,440

2,982

7,411

16,073

1,700

29,447








Weighted Average Shares
Outstanding (Basic and diluted)3

200,641

169,161

160,684

194,782

164,444

158,468

Shares Outstanding, December 313

201,469

169,983

160,883

201,469

169,983

160,883

1

See "Non-IFRS Measures" below.

2

Basic and diluted earnings per share is based on the profit or loss attributable to shareholders of Centric Health Corporation.

3

Excludes contingent escrowed shares and restricted shares

 

Consolidated Results

Consolidated Revenue from continuing operations for the three month period ended December 31, 2017 increased marginally by 1.2% to $42.3 million from $41.8 million. Revenue growth in Specialty Pharmacy was dampened due to timing differences in the transitions of certain contracts in Specialty Pharmacy due to the conclusion of a contract with a large long-term care and retirement home operator, and delay in the transition of beds due to a technical issue with a third-party supplier for a new large national customer expected to replenish the beds off-boarded from the concluded contract.  The on-boarding of beds under the new contract was substantially completed by the beginning of 2018, allowing for a return to a normalized revenue run-rate by the second quarter of 2018.

Adjusted EBITDA1 from continuing operations for the three month period ended December 31, 2017 decreased to $4.1 million from $4.4 million for the same period in the prior year. The decrease was primarily due to the transition of certain contracts noted above and additional labour costs resulting from the on-boarding of beds under the New Contract, partially offset by growth in the Surgical and Medical Centres segment.

Consolidated revenue from continuing operations for the year ended December 31, 2017 increased by 1.0%, or $1.6 million, to $169.0 million from $167.4 million for the same period in the prior year.  However, after normalizing for the $4.1 million reclassification of Revenue to cost of sales, Revenue increased by 3.4%.

Adjusted EBITDA from continuing operations for the year ended December 31, 2017 increased to $17.5 million compared to $15.6 million for the year ended December 31, 2016.

The increase in Revenue and Adjusted EBITDA for the year ended December 31, 2017 was primarily driven by Revenue growth in the Surgical and Medical Centres business through increased surgical volumes and a net increase in higher margin procedures performed.

Segment Results

(All amounts in the charts below are in thousands except per share, shares outstanding, and percentage data)

For the three month periods ended
December 31,

Revenue

Adjusted EBITDA1 from continuing
operations


2017

2016

2017


2016


(in $000)

$

$

$

%

$

%

Specialty Pharmacy

31,069

31,436

3,610

11.6

4,897

15.6

Surgical and Medical Centres

11,259

10,391

1,608

14.3

1,173

11.3

Corporate

?

?

(1,160)

?

(1,697)

?

Total

42,328

41,827

4,058

9.6

4,373

10.5

 

For the years ended December 31,

Revenue

Adjusted EBITDA1 from continuing
operations


2017

2016

2017


2016


(in $000)

$

$

$

%

$

%

Specialty Pharmacy

124,451

125,132

17,016

13.7

17,154

13.7

Surgical and Medical Centres

44,516

42,231

6,179

13.9

5,039

11.9

Corporate

?

?

(5,681)

?

(6,603)

?

Total

168,967

167,363

17,514

10.4

15,590

9.3

 

SHARES OUTSTANDING

As at December 31, 2017, the Company had total shares outstanding of 206,522,963. The outstanding shares at December 31, 2017 include 5,054,232 shares which are restricted or held in escrow and will be released to certain vendors of previously acquired businesses based on the achievement of certain stated performance targets and certain customers. Accordingly, for financial reporting purposes, the Company reported 201,468,731 common shares outstanding as at December 31, 2017 and 169,982,529 shares outstanding at December 31, 2016. The number of options outstanding is 2,347,500 at December 31, 2017. The number of restricted share units outstanding is 3,224,080 at December 31, 2017. The number of warrants outstanding is 2,972,000 at December 31, 2017. Should all outstanding options and warrants that were exercisable at December 31, 2017 be exercised, the Company would receive proceeds of $2.6 million.

As at the date of this press release, March 20, 2018, the Company had total shares outstanding of 207,139,399 which include 5,054,232 shares which are restricted or held in escrow. The number of options outstanding is 2,347,500; the number of warrants outstanding is 2,972,000; and the number of restricted share units outstanding is 2,993,246.

1NON-IFRS MEASURES

This press release includes certain measures which have not been prepared in accordance with IFRS such as EBITDA, Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EBITDA per share.  These non-IFRS measures are not recognized under IFRS and, accordingly, shareholders are cautioned that these measures should not be construed as alternatives to net income determined in accordance with IFRS.  The non-IFRS measures presented are unlikely to be comparable to similar measures presented by other issuers.

The Company defines EBITDA as earnings before depreciation and amortization, interest expense, amortization of lease incentives, and income tax expense (recovery).  Adjusted EBITDA is defined as EBITDA before transaction and restructuring costs, changes in the fair value of the contingent consideration liability, impairments, stock based compensation expense, change in fair value of derivative financial instruments and gain on disposal of property and equipment recognized in the statement of income. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenue. Adjusted EBITDA per share is defined as Adjusted EBITDA divided by the weighted outstanding shares on both a basic and diluted basis. The Company believes that Adjusted EBITDA1 is a meaningful financial metric as it measures cash generated from operations which the Company can use to fund working capital requirements, service interest and principal debt repayments and fund future growth initiatives.  The Company's agreements with senior lenders are structured with certain financial performance covenants which includes Adjusted EBITDA1 as a key component of the covenant calculations. EBITDA and Adjusted EBITDA1 are not recognized measures under IFRS.

Reconciliation of Non-IFRS Measures


For the three month
periods ended December
31,

For the years ended
December 31,


2017

2016

2017

2016

(in $000)

$

$

$

$

Income (loss) from continuing operations

3,702

(1,423)

(520)

(18,276)

Depreciation and amortization

2,394

2,517

9,522

11,642

Interest expense

1,485

3,157

9,902

18,348

Amortization of lease incentives

89

(51)

(50)

(264)

Income tax recovery

(1,388)

(1,208)

(1,483)

(8,872)

EBITDA from continuing operations

6,282

2,992

17,371

2,578

Transaction and restructuring costs

1,938

1,094

6,061

6,803

Change in fair value of contingent consideration
liability

(4,352)

(169)

(6,047)

5,238

Reversal of impairment losses

?

?

(322)

?

Stock-based compensation expense

282

234

938

790

Change in fair value of derivative financial 
instruments

(90)

228

(534)

188

Gain (loss) on disposal of property and equipment

(2)

(6)

47

(7)

Adjusted EBITDA from continuing operations

4,058

4,373

17,514

15,590

Adjusted EBITDA from discontinued operations

?

(10)

?

(124)

Adjusted EBITDA

4,058

4,363

17,514

15,466

Basic and diluted weighted average number of
shares

200,641

169,161

194,782

164,444

Adjusted EBITDA per share from continuing
operations (basic and diluted)

$0.02

$0.03

$0.09

$0.09

Adjusted EBITDA per share (basic and diluted)

$0.02

$0.03

$0.09

$0.09

 

PRESENTATION OF FINANCIAL RESULTS

The Company presents two reportable operating segments as follows: Specialty Pharmacy and Surgical and Medical Centres. The financial results of the Company's Performance Medical Group, are included as part of the Surgical and Medical Centres segment.

CONFERENCE CALL

Centric Health will host a conference call, including a slide presentation, to discuss its fourth quarter financial results on Wednesday, March 21, 2017 at 9:30 a.m. (ET).

Telephone Dial-In Access Information

To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191.  Please connect approximately 10 minutes prior to the beginning of the call to ensure participation.  Those participating in the conference call by telephone can view the slide presentation by accessing the online webcast (see instructions below) and choosing the Non-Streaming Audio option.

Webcast Access Information

A live webcast of the conference call, including the slide presentation, will be available on the Events and Presentations page of the Investors section of the Company's web site (http://www.centrichealth.ca/investors/events-and-presentations.html).  Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. To view the webcast presentation with slides, please choose either the Real Streaming Audio or Windows Streaming Audio option.

Archive Access Information

The conference call will be archived for replay by telephone until Wednesday, March 28, 2018 at midnight.  To access the archived conference call, dial 1-855-859-2056 or 416-849-0833 and enter the reservation number   8564256.

The webcast with slide presentation will be archived for 90 days on the Events and Presentations page of the Investors section of the Company's web site (http://www.centrichealth.ca/investors/events-and-presentations.html).

For further information please refer to the Company's complete filings at www.sedar.com.

About Centric Health

Centric Health's vision is to be Canada's most respected and recognized provider in the independent healthcare sectors in which it operates, world renowned for delivering the highest levels of quality care and outcomes, innovative solutions and value to patients, clients and stakeholders. To this end, Centric Health primarily focuses on two core healthcare businesses:

With national networks of facilities in each of its businesses, deep knowledge and experience of healthcare delivery and extensive, trusted relationships with payers, physicians, and government agencies, the Company is uniquely positioned to address current and future healthcare needs in growing markets as the Canadian healthcare industry goes through a major transformation over the medium to long term.

This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable Canadian securities legislation.  These forward-looking statements include, among others, statements regarding business strategy, plans and other expectations, beliefs, goals, objectives, information and statements about possible future events. Readers are cautioned not to place undue reliance on such forward-looking statements. Forward-looking statements are based on current expectations, estimates and assumptions that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Centric Health and described in the forward-looking statements contained in this press release. No assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur or, if any of them do so, what benefits Centric Health will derive there-from.

SOURCE Centric Health Corporation


These press releases may also interest you

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...



News published on and distributed by: